

## Product Information

### Anti-Interleukin-12

produced in goat, IgG fraction of antiserum

Catalog Number **I7642**

#### Product Description

Anti-Interleukin-12 (IL-12) is developed in goat using recombinant mouse IL-12 expressed in the insect cell line Sf 21 as immunogen. The antibody is purified by Protein G affinity chromatography.

Anti-Interleukin-12 may be used in immunoblotting, ELISA, and neutralization. By ELISA, the antibody shows <10% cross-reactivity with recombinant human IL-12 and <5% cross-reactivity with recombinant porcine IL-12.

Interleukin-12 (IL-12) or Natural Killer Cell Stimulatory Factor (NKSF) is a disulfide-linked heterodimer of a 35 kDa light chain subunit and 40 kDa heavy chain subunit. The molecular mass of IL-12 is approximately 75 kDa. The p35 subunit of IL-12 shares amino acid sequence homology with IL-6 and G-CSF.<sup>2</sup> The p40 subunit has homology to the extracellular domain of the IL-6 receptor and to the ciliary neurotrophic growth factor receptor.<sup>3,4</sup> IL-12 is produced predominantly by monocytes and NK cells.<sup>1</sup> IL-12 induces T cells and NK cells to produce IFN- $\gamma$ . Human IL-12 is not active on mouse cells, but mouse IL-12 is active on both mouse and human lymphocytes.<sup>4</sup>

#### Reagent

Lyophilized from 0.2  $\mu$ m-filtered solution in phosphate buffered saline containing carbohydrates.

#### Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

#### Preparation Instructions

To one vial of lyophilized powder, add 1 mL of 0.2  $\mu$ m filtered phosphate buffered saline to produce a 1 mg/mL stock solution of the antibody. If aseptic technique is used, no further filtration should be needed for use in cell culture environments.

#### Storage/Stability

Prior to reconstitution, store at  $-20^{\circ}\text{C}$ . Reconstituted product may be stored at  $2-8^{\circ}\text{C}$  for up to one month. For prolonged storage, freeze in working aliquots at  $-20^{\circ}\text{C}$ . Avoid repeated freezing and thawing.

#### Procedure

Anti-Interleukin-12 is tested for its ability to neutralize the biological activity of recombinant mouse IL-12 on mouse splenocytes.<sup>5</sup> In this bioassay, 0.3 ng/mL recombinant mouse IL-12 is mixed with various dilutions of antibody in a 96-well plate for 1 hour at  $37^{\circ}\text{C}$ . After preincubation, mouse splenocytes ( $2 \times 10^5$ ) and 10 ng/mL PMA are added to the antigen-antibody mixture. The assay mixture, in a total volume of 100  $\mu$ L, is incubated at  $37^{\circ}\text{C}$  for 48 hours in a humidified  $\text{CO}_2$  incubator and pulsed during the final 4 hours with  $^3\text{H}$ -thymidine. Cells are harvested onto glass filters and the  $^3\text{H}$ -thymidine incorporation into DNA is measured.

The Neutralization Dose<sub>50</sub> (ND<sub>50</sub>) of the antibody is defined as the concentration of antibody resulting in a one-half maximal inhibition of bioactivity of recombinant mouse IL-12 that is present at a concentration just high enough to elicit a maximum response.

#### Product Profile

**ELISA:** a working concentration of 0.5-1.0  $\mu\text{g/mL}$  detects  $\sim 1$  ng/well of recombinant mouse IL-12.

**Immunoblotting:** a working concentration of 1-2  $\mu\text{g/mL}$  detects mouse IL-12. The detection limit for recombinant mouse IL-12 is  $\sim 20$  ng/lane under non-reducing conditions. Under reducing conditions, the p40 and p35 bands from 20 ng/lane of recombinant mouse IL-12 can also be detected. Because this antibody preparation is a total IgG fraction, complete monospecificity cannot be assumed.

Endotoxin:  $<10$  ng/vial by LAL method

## References

1. Trinchieri, G., et al., *Progress in Growth Factor Research*, **4**, 355, (1992).
2. Merberg, D., et al., *Immunol. Today*, **13**, 77 (1992).
3. Gearing, D., et al., *Cell*, **66**, 9 (1991).
4. Schoenhaut, D., et al., *J. Immunol.*, **148**, 3433 (1992).
5. Mattner, F., et al., *Eur. J. Immunol.*, **23**, 2202 (1993).

KAA,PHC,TMS 06/16-1